Walleye Capital’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.53M Sell
2,205,649
-1,062,363
-33% -$2.02M ﹤0.01% 2260
2026
Q2
$6.8M Buy
+3,268,012
New +$7.18M 0.02% 655
2024
Q1
– Sell
-69,411
Closed -$223K – 5380
2023
Q4
$223K Buy
+69,411
New +$197K ﹤0.01% 3612
2023
Q3
– Sell
-115,032
Closed -$572K – 4826
2023
Q2
$572K Buy
115,032
+11,597
+11% +$62.7K ﹤0.01% 2332
2023
Q1
$511K Buy
+103,435
New +$663K 0.01% 1701
2020
Q3
– Sell
-16,536
Closed -$708K – 817
2020
Q2
$708K Buy
+16,536
New +$598K 0.16% 164

Other funds holding ALLO

Walleye Capital's ALLO Position: Q3 2026 in Review

Walleye Capital reduced its Allogene Therapeutics (ALLO) stake by 33% in Q3 2026, selling an estimated $2.02M and leaving 2,205,649 shares worth $3.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2260.

Walleye Capital first reported a position in ALLO in Q2 2020 and has held it in 6 quarters since. The position peaked at $6.8M in Q2 2026. 196 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Walleye Capital held 2,205,649 shares of Allogene Therapeutics worth $3.53M as of Q3 2026.
  • Walleye Capital sold 1,062,363 Allogene Therapeutics shares in Q3 2026, an estimated $2.02M.
  • Allogene Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #2260 holding.
  • Walleye Capital first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • Walleye Capital's Allogene Therapeutics position peaked at $6.8M in Q2 2026.
  • 196 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.